Who Buys Teicoplanin from India — 108 Importers Behind a $6.3M Market

The importation of Teicoplanin from India involves various buyer segments, each with distinct purchasing behaviors and order patterns.

Distributors: Entities such as Austell Pharmaceuticals (Pty) Ltd in South Africa and Hanse Service Internationale in Germany function as distributors. They procure Teicoplanin in bulk to supply hospitals, clinics, and pharmacies within their respective regions. Their purchasing behavior is characterized by large-volume orders, often through tender processes, to ensure a steady supply chain and meet the demands of multiple healthcare providers.

Government Procurement Agencies: Organizations like Medicuba S.A. in Cuba and People's Bank in Sri Lanka represent government procurement agencies. They acquire Teicoplanin to distribute within public healthcare systems, often through national tenders or agreements. Their order patterns are typically large and periodic, aligning with government budget cycles and healthcare program needs.

Hospital Groups: Slim Pharmaceuticals (Pvt) Ltd and Yaden International (Pvt) Ltd in Sri Lanka, as well as Medpro Pharmaceutica Pty Ltd in South Africa, are likely associated with hospital groups. They purchase Teicoplanin to meet the specific needs of their affiliated hospitals, focusing on ensuring the availability of essential antibiotics for patient care. Their purchasing behavior includes regular orders based on hospital demand and treatment protocols.

Hungary:

1. Drug Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).

2. Import Registration Process for Teicoplanin: Importers must submit a marketing authorization application to OGYÉI, including comprehensive data on the drug's quality, safety, and efficacy. The process involves dossier evaluation, potential inspections, and compliance with EU regulations.

3. Estimated Timeline for Registration: Approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: As an EU member, Hungary applies the EU's Common External Tariff, which may allow for duty-free importation of pharmaceutical products under HS code 30042099.

Sri Lanka:

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Teicoplanin: Importers are required to obtain registration from NMRA by submitting an application with detailed information on the product, including manufacturing details, quality control measures, and clinical data.

3. Estimated Timeline for Registration: Approximately 6 to 12 months, depending on the review process and any additional information required.

4. Import Tariff/Duty for HS 30042099: Pharmaceutical products under HS code 30042099 are typically subject to a duty of 0% to 15%, depending on the specific product and applicable trade agreements.

South Africa:

1. Drug Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).

2. Import Registration Process for Teicoplanin: Importers must apply for registration with SAHPRA, providing comprehensive data on the product's quality, safety, and efficacy. The process includes dossier evaluation and potential facility inspections.

3. Estimated Timeline for Registration: Approximately 12 to 24 months, subject to the complexity of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: Pharmaceutical products under HS code 30042099 are generally subject to a duty of 0%, aligning with South Africa's commitment to facilitating access to essential medicines.

Cuba:

1. Drug Regulatory Authority: Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED).

2. Import Registration Process for Teicoplanin: Importers must submit a registration application to CECMED, including detailed information on the product's quality, safety, and efficacy. The process involves dossier evaluation and compliance with national health regulations.

3. Estimated Timeline for Registration: Approximately 12 months, depending on the completeness of the application and any additional information required.

4. Import Tariff/Duty for HS 30042099: Cuba applies import duties on pharmaceutical products, which can vary; specific rates for HS code 30042099 should be confirmed with Cuban customs authorities.

Germany:

1. Drug Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process for Teicoplanin: Importers must obtain a marketing authorization from BfArM, submitting a comprehensive dossier that includes data on the drug's quality, safety, and efficacy. The process aligns with EU regulations and may involve mutual recognition procedures.

3. Estimated Timeline for Registration: Approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: As an EU member, Germany applies the EU's Common External Tariff, which may allow for duty-free importation of pharmaceutical products under HS code 30042099.

The demand for Teicoplanin in importing countries is driven by several factors:

1. Disease Prevalence: Teicoplanin is an antibiotic used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). The prevalence of such infections necessitates the availability of effective antibiotics like Teicoplanin.

2. Government Healthcare Programs: Many countries have implemented programs to combat antimicrobial resistance and ensure the availability of essential antibiotics. For instance, the WHO's AWaRe classification system, updated in 2019, categorizes antibiotics to guide their appropriate use and procurement. Teicoplanin falls into the 'Watch' category, indicating its importance in treating specific infections and the need for careful monitoring of its use. (who.int)

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage have led to increased procurement of essential medicines, including antibiotics. Countries are investing in their healthcare systems to provide comprehensive care, which includes access to critical medications like Teicoplanin.

4. WHO Essential Medicines List Procurement: The WHO Model List of Essential Medicines serves as a guide for countries to develop their national lists. The 2019 update included revisions to the AWaRe classification, emphasizing the need for access to a range of antibiotics, including those in the 'Watch' category like Teicoplanin. (who.int)

5. Tender-Based Purchasing: Many countries utilize tendering processes to procure medicines for their public healthcare systems. This approach ensures competitive pricing and consistent supply of essential medicines. For example, South Africa employs a centralized tender system for pharmaceutical procurement, which has been effective in standardizing processes and achieving economies of scale.

With 108 buyers across 44 countries importing Teicoplanin from India, there is a significant market opportunity. The repeat buyer rate of 62.0% indicates sustained demand and satisfaction with the product, suggesting potential for continued growth in these markets.

The importation of Teicoplanin from India involves various buyer segments, each with distinct purchasing behaviors and order patterns.

Distributors: Entities such as Austell Pharmaceuticals (Pty) Ltd in South Africa and Hanse Service Internationale in Germany function as distributors. They procure Teicoplanin in bulk to supply hospitals, clinics, and pharmacies within their respective regions. Their purchasing behavior is characterized by large-volume orders, often through tender processes, to ensure a steady supply chain and meet the demands of multiple healthcare providers.

Government Procurement Agencies: Organizations like Medicuba S.A. in Cuba and People's Bank in Sri Lanka represent government procurement agencies. They acquire Teicoplanin to distribute within public healthcare systems, often through national tenders or agreements. Their order patterns are typically large and periodic, aligning with government budget cycles and healthcare program needs.

Hospital Groups: Slim Pharmaceuticals (Pvt) Ltd and Yaden International (Pvt) Ltd in Sri Lanka, as well as Medpro Pharmaceutica Pty Ltd in South Africa, are likely associated with hospital groups. They purchase Teicoplanin to meet the specific needs of their affiliated hospitals, focusing on ensuring the availability of essential antibiotics for patient care. Their purchasing behavior includes regular orders based on hospital demand and treatment protocols.

Hungary:

1. Drug Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).

2. Import Registration Process for Teicoplanin: Importers must submit a marketing authorization application to OGYÉI, including comprehensive data on the drug's quality, safety, and efficacy. The process involves dossier evaluation, potential inspections, and compliance with EU regulations.

3. Estimated Timeline for Registration: Approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: As an EU member, Hungary applies the EU's Common External Tariff, which may allow for duty-free importation of pharmaceutical products under HS code 30042099.

Sri Lanka:

1. Drug Regulatory Authority: National Medicines Regulatory Authority (NMRA).

2. Import Registration Process for Teicoplanin: Importers are required to obtain registration from NMRA by submitting an application with detailed information on the product, including manufacturing details, quality control measures, and clinical data.

3. Estimated Timeline for Registration: Approximately 6 to 12 months, depending on the review process and any additional information required.

4. Import Tariff/Duty for HS 30042099: Pharmaceutical products under HS code 30042099 are typically subject to a duty of 0% to 15%, depending on the specific product and applicable trade agreements.

South Africa:

1. Drug Regulatory Authority: South African Health Products Regulatory Authority (SAHPRA).

2. Import Registration Process for Teicoplanin: Importers must apply for registration with SAHPRA, providing comprehensive data on the product's quality, safety, and efficacy. The process includes dossier evaluation and potential facility inspections.

3. Estimated Timeline for Registration: Approximately 12 to 24 months, subject to the complexity of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: Pharmaceutical products under HS code 30042099 are generally subject to a duty of 0%, aligning with South Africa's commitment to facilitating access to essential medicines.

Cuba:

1. Drug Regulatory Authority: Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos (CECMED).

2. Import Registration Process for Teicoplanin: Importers must submit a registration application to CECMED, including detailed information on the product's quality, safety, and efficacy. The process involves dossier evaluation and compliance with national health regulations.

3. Estimated Timeline for Registration: Approximately 12 months, depending on the completeness of the application and any additional information required.

4. Import Tariff/Duty for HS 30042099: Cuba applies import duties on pharmaceutical products, which can vary; specific rates for HS code 30042099 should be confirmed with Cuban customs authorities.

Germany:

1. Drug Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).

2. Import Registration Process for Teicoplanin: Importers must obtain a marketing authorization from BfArM, submitting a comprehensive dossier that includes data on the drug's quality, safety, and efficacy. The process aligns with EU regulations and may involve mutual recognition procedures.

3. Estimated Timeline for Registration: Approximately 210 days, subject to the completeness of the application and any additional information requests.

4. Import Tariff/Duty for HS 30042099: As an EU member, Germany applies the EU's Common External Tariff, which may allow for duty-free importation of pharmaceutical products under HS code 30042099.

The demand for Teicoplanin in importing countries is driven by several factors:

1. Disease Prevalence: Teicoplanin is an antibiotic used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA). The prevalence of such infections necessitates the availability of effective antibiotics like Teicoplanin.

2. Government Healthcare Programs: Many countries have implemented programs to combat antimicrobial resistance and ensure the availability of essential antibiotics. For instance, the WHO's AWaRe classification system, updated in 2019, categorizes antibiotics to guide their appropriate use and procurement. Teicoplanin falls into the 'Watch' category, indicating its importance in treating specific infections and the need for careful monitoring of its use. (who.int)

3. Universal Health Coverage Expansion: Efforts to expand universal health coverage have led to increased procurement of essential medicines, including antibiotics. Countries are investing in their healthcare systems to provide comprehensive care, which includes access to critical medications like Teicoplanin.

4. WHO Essential Medicines List Procurement: The WHO Model List of Essential Medicines serves as a guide for countries to develop their national lists. The 2019 update included revisions to the AWaRe classification, emphasizing the need for access to a range of antibiotics, including those in the 'Watch' category like Teicoplanin. (who.int)

5. Tender-Based Purchasing: Many countries utilize tendering processes to procure medicines for their public healthcare systems. This approach ensures competitive pricing and consistent supply of essential medicines. For example, South Africa employs a centralized tender system for pharmaceutical procurement, which has been effective in standardizing processes and achieving economies of scale.

With 108 buyers across 44 countries importing Teicoplanin from India, there is a significant market opportunity. The repeat buyer rate of 62.0% indicates sustained demand and satisfaction with the product, suggesting potential for continued growth in these markets.